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Background: Cerebral autosomal-dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL) is the most common genetic cause of stroke. In addi-
tion to ischemic stroke, CADASIL predisposes to development of cerebral microbleeds 
(CMB). CMB and hypertension are known to be associated with intracerebral hemor-
rhage (ICH). The purpose of this study was to analyze the relationships among CMB, 
hypertension, and ICH in CADASIL.
Materials and methods: We enrolled 94 genetically confirmed CADASIL patients from 
76 unrelated families at Jeju National University Hospital (Korea) between March 2012 
and February 2015. We analyzed CMB presence, number, and distribution on suscep-
tibility-weighted imaging MRI using the microbleed anatomical rating scale. Multiple 
logistic regression was used to determine factors associated with the presence of CMB 
and ICH.
results: CMB were observed in 62 patients (66%), median number of CMB per patient 
was 4 (range 0–121). Twenty-two ICHs were found in 16 patients (17%). There was 
incongruence between the most common site of CMB (thalamus) and that of ICH (basal 
ganglia). Hypertension was independently associated with the presence of CMB (multi-
ple regression OR, 2.71; 95% CI 1.02–7.18, p < 0.05), and CMB ≥ 9 (highest third) was 
significantly associated with the presence of ICH (multiple regression OR = 9.50, 95% 
CI 1.08–83.71, p < 0.05).
conclusion: In this CADASIL sample, presence of hypertension was independently 
associated with CMB presence, and CMB burden was independently associated with 
ICH. Incongruence of sites for CMB and ICH is currently unexplained and requires further 
study.
Keywords: caDasil, microbleeds, hypertension, intracerebral hemorrhage, stroke
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inTrODUcTiOn
Cerebral autosomal-dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) is the most 
common genetic cause of stroke. In addition to ischemic stroke, 
CADASIL predisposes to development of cerebral microbleeds 
(CMB) (1–3). CMB are well-defined MRI-demonstrable brain 
lesions consisting of tiny perivascular hemosiderin deposits, 
detectable using T2*-weighted gradient echo or susceptibility-
weighted imaging (SWI) (4). CMB are associated with hyper-
tension, cerebral amyloid angiopathy (CAA), and chronic 
kidney disease (5). CMB are also associated with intracerebral 
hemorrhage (ICH), which accounts for 20–30% of stroke in Asian 
countries such as Korea and Japan (6). Hypertension and CAA 
are the most common causes of ICH, and CAA is known to be 
associated with apolipoprotein E (ApoE)-ε4 genotype (7).
The presence of hemorrhagic phenomena in CADASIL cre-
ates clinical concerns, including potential use of antithrombotic 
treatments. In the current study, we investigated hemorrhagic 
complications of CADASIL. We analyzed the relationships 
among hypertension, CMB, and ICH, as well as the roles of other 
vascular factors including ApoE genotype. We hypothesized 
that hypertension and CMB would be independently associated 
with ICH, known to occur in 12–25% of East-Asian CADASIL 
patients (8–10). We also hypothesized that CMB would colocalize 
with ICH.
MaTerials anD MeThODs
We studied consecutive patients diagnosed with CADASIL by 
mutation of NOTCH3 gene (11) at Jeju National University 
Hospital’s Neurology Department (Korea) between March 
2012 and February 2015. Asymptomatic as well as symptomatic 
patients were included in the study. This study was carried out in 
accordance with the recommendations of and approved by the 
Institutional Review Board of Jeju National University Hospital. 
All subjects gave written informed consent in accordance with 
the Declaration of Helsinki.
Symptomatic patients had been diagnosed with CADASIL 
based on CADASIL symptoms (ischemia or hemorrhagic epi-
sode, cognitive impairment, chronic headache, and/or seizure). 
Asymptomatic patients had at least one symptomatic family 
member. Vascular risk factors were recorded in all patients. 
Hypertension was defined as blood pressure >140/90  mm Hg 
on more than one occasion or use of antihypertensive agent. 
Diabetes mellitus was defined as fasting glucose level ≥126 mg/
dl, PP2 test level ≥200 mg/dl, or use of anti-diabetes medication. 
Hypercholesterolemia was defined as total serum cholesterol 
level >240  mg/dl. In addition, a medication history, including 
use of platelet medications, was taken on the day of examination. 
ApoE genotype was determined in all patients (12).
All patients had one MRI study acquired on a 3  T scanner 
(Achieva, Philips Healthcare, Best, Holland) using a 32-chan-
nel array head coil. A volume isotropic TSE (turbo spin echo) 
acquisition technique was used for 3D FLAIR imaging. The 
parameters for 3D FLAIR imaging were as follows: TR/TE, 
4,800/320  ms; TI, 1,650  ms; turbo factor, 240; spatial 
resolution, 1  mm ×  1  mm ×  1  mm; reconstructed resolution, 
1 mm × 1 mm × 0.5 mm; and SENSE factor, 5. The acquisition time 
for 3D FLAIR was about 6 min 48 s. A 3D T1-weighted turbo field 
echo (TFE) acquisition technique was used for 3D T1-weighted 
imaging. The parameters for 3D T1 TFE were as follows: TR/TE, 
8/4 ms; flip angle, 8°; spatial resolution, 1 mm × 1 mm × 1 mm; 
reconstructed resolution, 1 mm × 1 mm × 0.5 mm; and SENSE 
factor, 2: acquisition time, 5  min. SWI was performed for the 
evaluation of microbleeds. The detailed image parameters for 
SWI were as follows: flow-compensated three-dimensional 
gradient-echo sequence; TR/TE, 15/21 ms; flip angle, 15°; FOV, 
210 mm × 210 mm; matrix, 280 × 280; section thickness, 2 mm; 
slab thickness, 150  mm; SENSE factor, 2; and total acquisition 
time, 2 min 51 s. Axial TSE T2-weighted imaging was acquired 
(TR/TE, 3,200/80 ms). In addition, head CT scans (Siemens) were 
performed at the time of symptomatic ICH.
One experienced neuroradiologist (Ho Kyu Lee), blinded to 
clinical data, reviewed all MRI and rated definite CMB presence, 
number, and distribution on SWI using the Microbleed Anatomical 
Rating Scale (MARS) (13). He read 50 brain MRI twice, 1 week 
apart, and the intrarater reliabilities (Kappa statistic, intraclass 
correlation coefficient) were calculated for presence, tertiles, and 
number of CMB. In MARS, definite CMB were defined as small, 
rounded or circular, well-defined hypodense lesions within brain 
parenchyma with clear margins ranging from 2 to 10 mm in size 
on T2*-weighted images, and locations of CMB were classified 
into deep, lobar, and infratentorial categories. CMB mimics were 
carefully excluded using all available images. ICH was defined as 
spontaneous non-traumatic bleeding into the brain parenchyma 
without secondary causes. It was diagnosed on the basis of neu-
roimaging (CT images at symptomatic ICH onset or MR images 
at examination including SWI, T1WI, T2WI, and FLAIR) by one 
neuroradiologist (Ho Kyu Lee) and confirmed by a second neu-
roradiologist (David Floriolli). Asymptomatic ICH was defined 
as MRI (including SWI, T1WI, T2WI, and FLAIR) documented 
hemorrhage without associated symptoms. Data were analyzed 
using SPSS statistical software (version 20.0). Variables in Table 1 
(all dichotomous except age, education, SBP, and DBP) with a 
p-value < 0.2 on simple regression analysis were considered as 
potential independent variables to determine whether or not 
hypertension or other factors were associated with the presence 
of CMB and whether or not hypertension, CMB tertile, or other 
factors were associated with the presence of ICH. Stepwise back-
ward logistic regression of variables was performed to obtain a 
final model of significant (p < 0.05) independent variables. CMB 
count, not normally distributed, was categorized according to 
tertiles and an ordinal logistic regression was also performed.
resUlTs
We studied 94 patients with genetically confirmed CADASIL, 
excluding three patients who could not complete MRI. These 
patients were from 76 families, and 89 patients (95%) had a R544C 
mutation, followed by R578C in 2 patients (2%), R75P in 2 patients 
(2%), and C452A in 1 patient (1%). Clinical characteristics of the 
94 patients are summarized in Table 1; 52 patients were men (55%) 
and mean ± SD age of the patients was 62.6 ± 12.5 years (range 
TaBle 1 | clinical characteristics of 94 patients with caDasil.
Mean ± sD, median
Age, years 62.6 ± 12.5, 64.0
Education, years 9.3 ± 0.6, 12.0
Systolic blood pressure (mmHg) 122.8 ± 12.4, 123.0
Diastolic blood pressure (mmHg) 75.1 ± 9.7, 74.5
Number of CMB 9.7 ± 17.5, 4.0
n (%)
Males 52 (55)
ApoE ε4 30 (32)
Hypertension 50 (53)
Diabetes mellitus 16 (17)
Hypercholesterolemia 24 (26)
Atrial fibrillation 3 (3)
Platelet medication use 60 (64)
Anticoagulant use 2 (2)
Ever-smoking 36 (37)
CMB 62 (66)
Intracerebral hemorrhage 16 (17)
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; ApoE, apolipoprotein E; CMB, cerebral microbleeds.
FigUre 1 | Proportion of cerebral microbleeds (cMB) and intracerebral hemorrhage (ich) by each location of brain. CMB radar plots (black line) show 
the most common site was thalamus (36%). ICH radar plots (gray line) show that the most common site was basal ganglia (41%).
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34–90). Hypertension was present in 50 patients (53%). The ApoE 
genotype frequencies were ε2/ε2 1 (1%); ε2/ε3 8 (9%); ε2/ε4 2 (2%); 
ε3/ε3 55 (59%); ε3/ε4 27 (29%); and ε4/ε4 1 (1%). Platelet medica-
tions included aspirin (n =  16), clopidogrel (n =  25), cilostazol 
(n = 14), triflusal (n = 2), combination of aspirin and clopidogrel 
(n = 1), and combination of aspirin and cilostazol (n = 2).
Intrarater reliabilities for CMB presence and number were 
excellent (Kappa statistic = 0.94 for presence and 0.97 for tertiles; 
intraclass correlation coefficient for number  =  0.97, 95% CI 
0.95–0.98). CMB were detected in 66% (62 out of 94). The number 
of CMB per patient ranged from 0 to 121 (median 4.0). Tertiles 
for CMB count gave: lowest third 0 CMB, middle third 1–8 CMB, 
and highest third ≥9 CMB. Among 958 CMB, 341 (36%) were 
located in the thalamus, 298 (31%) were lobar, 106 (11%) in the 
basal ganglia, 83 (9%) in the brainstem, 42 (4%) in cerebellum, 
39 (4%) in deep periventricular white matter, 28 (3%) in internal 
capsule, and 21 (2%) in external capsule. Among the patients with 
CMB, 3% had strictly lobar CMB, 15% strictly deep CMB, and 
2% strictly infratentorial CMB, whereas 80% had mixed CMB. 
Twenty-two ICHs were found in 16 patients (17%). Among 22 
ICH, 9 (41%) were located in the basal ganglia, 5 (23%) in the 
thalamus, 4 (18%) in the lobar, 2 (9%) in the cerebellum, and 2 
(9%) in pons (Figures 1 and 2). Four ICH were asymptomatic in 
four patients. The site of asymptomatic ICH was pons (n = 2), 
basal ganglia (n = 1), and lobar area (n = 1). Nine of 22 ICH (41%) 
had CMB in the same location as the ICH; 3 of 9 ICH in basal 
ganglia (33%) had CMB in the same location (Figures 1 and 2).
Age (continuous), ApoE genotype (ApoE-ε4 vs non-ApoE-ε4), 
hypertension, and platelet medication use were associated 
(p < 0.2) on simple logistic regression analysis with the presence 
of CMB (Table  2) and were, therefore, included as potential 
independent variables in the multiple logistic regression analysis 
for CMB (Table 3). Hypertension was independently associated 
with the presence of CMB (multiple regression OR, 2.71; 95% CI, 
1.02–7.18;  p = 0.045). Although platelet medication use was related 
to the presence of any CMB in simple logistic regression analysis 
(OR, 3.00; 95% CI, 1.23–7.31; p = 0.016), it was not significantly 
related in the final multiple logistic regression model. Age was 
independently associated with the presence of CMB (multiple 
regression OR, 1.06; 95% CI, 1.02–1.11; p = 0.006). Ordinal logistic 
regression of CMB tertile gave similar results: only hypertension 
(p = 0.0005) and age (p = 0.03) were significantly associated with 
CMB tertile. However, age was not associated with the presence of 
ICH in simple logistic regression analysis (p = 0.57). The highest 
CMB count group (≥9) was significantly associated with the pres-
ence of ICH (multiple regression OR = 9.50; 95% CI, 1.08–83.71; 
p = 0.043) (Table 3). Hypertension was related to the presence 
TaBle 2 | simple logistic regression odds ratios and 95% confidence 
intervals for presence of cMB and for ich in 94 patients with caDasil.†
cMB
Age 1.07 (1.03–1.17)**
APOE-ε4 2.11 (0.79–5.63)
Hypertension 4.00 (1.61–9.94)**
Platelet medication use 3.00 (1.23–7.31)*
ich
Age 1.01 (0.97–1.06)
APOE-ε4 2.55 (0.85–7.63)
Hypertension 4.80 (1.27–18.2)*
Platelet medication use 0.68 (0.23–2.03)
cMB burden (tertiles)
I (CMB = 0) 1.00 (reference)
II (CMB = 1–8) 6.20 (0.68–56.6)
III (CMB ≥ 9) 14.09 (1.68–118)*
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; APOE-ε4, apolipoprotein E-ε4; CMB, cerebral microbleeds; ICH, 
intracerebral hemorrhage.
†Only variables with p < 0.2 are presented in the table.
*p < 0.05, **p < 0.01.
FigUre 2 | axial brain cT and matching susceptibility-weighted images (sWi) of six caDasil patients with intracerebral hemorrhage (ich) (a–r). 
SWI (a–F) shows cerebral microbleeds without ICH. SWI (g–l) and matching unenhanced brain CT (M–r) demonstrate acute ICH with or without intraventricular 
hemorrhage. Panels (a,g,M) are patient 1. (B,h,n) are patient 2. (c,i,O) are patient 3. (D,J,P) are patient 4. (e,K,Q) are patient 5. (F,l,r) are patient 6.
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of ICH in simple logistic regression analysis (OR, 4.80; 95% CI, 
1.27–18.19; p = 0.021) (Table 2), but not significantly related in 
the final multiple logistic regression model (p = 0.12).
DiscUssiOn
We found that hypertension and age were independently asso-
ciated with the presence of CMB in patients with CADASIL. 
We also found that the highest CMB count group (≥9) was 
independently associated with the presence of ICH. In addition, 
there was a mismatch between the most common site of CMB 
and ICH.
We observed that hypertension was independently associated 
with the presence of CMB (p = 0.045). This is in line with earlier 
studies (14, 15). In this study, we used MARS and SWI, which are 
known to increase the number and presence of CMB detected 
(16, 17). We observed excellent intrarater reliability for number 
of CMB, and prior work has shown excellent inter-rater reliability 
for CMB on SWI using MARS (18). Also, our results are consist-
ent with a recent meta-analysis showing significant correlation 
between hypertension and CMB in patients with stroke and in a 
healthy population (19).
In the present study, we show that age was associated with the 
presence of CMB. Recent studies of the relationship between age 
and presence of CMB in CADASIL have produced conflicting 
results (2, 3, 14, 15). However, pathological analysis has shown 
that cerebral microhemorrhages are common in aging brain, 
regardless of presence of hypertension or CAA (20). Moreover, 
CMB increases with age for all locations in a general popula-
tion (21), and age may be compounded by important vascular 
comorbidities for development of CMB (22, 23). Both CADASIL 
and hypertension have important effects on arteriolar function, 
with both processes targeting vascular smooth muscle cells (5).
We demonstrated that 17% of patients had primary ICH 
(n = 16); all had R544C mutation, and 14 had history of hyperten-
sion. In a Taiwanese series of 112 CADASIL patients in which 
R544C accounted for 71% of the mutation, the occurrence of ICH 
TaBle 3 | Multiple logistic regression odds ratios and 95% confidence 
intervals for significant factors relating to the presence of cMB and ich 
in 94 patients with caDasil.
cMB
Age 1.06 (1.02–1.11)**
Hypertension 2.71 (1.02–7.18)*
ich
cMB burden (tertiles)
I (CMB = 0) 1.00 (reference)
II (CMB = 1–8) 5.03 (0.53–47.1)
III (CMB ≥ 9) 9.50 (1.08–83.7)*
CADASIL, cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy; CMB, cerebral microbleeds; ICH, intracerebral hemorrhage.
*p < 0.05, **p < 0.0.1.
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did not differ between R544C mutation group and non-R544C 
mutation group (9). However, unlike East-Asian CADASIL 
patients, ICH has rarely been reported in Caucasian CADASIL 
patients (24). Recent work described four unrelated Caucasian 
CADASIL patients with ICH (25), all of whom had history of 
hypertension. Nine Caucasian CADASIL cases with ICH have 
been reported, and all showed various NOTCH3 mutations (25). 
Therefore, it is unclear whether ICH occurrence in CADASIL 
patients was due to specific NOTCH3 mutation.
We found that CMB burden (≥9) was independently associated 
with the presence of ICH (p =  0.043). CMB may predict sub-
sequent recurrent ICH in patients with previous lobar ICH 
(4, 18, 26). In addition, recent meta-studies have shown that 
CMB burden (≥10) on pretreatment MRI increases the risk 
of post-thrombolysis ICH during IV thrombolysis (27). Our 
findings are consistent with these observations suggesting that 
CMB burden predisposes to ICH.
There was a mismatch between the most common site of 
CMB and ICH in CADASIL in our study. The most common 
site of CMB was thalamus, followed by lobar, and basal ganglia. 
However, the most common site of ICH was basal ganglia, fol-
lowed by thalamus, and lobar area. Because the presence of ICH 
may mask the presence of CMB, the topographic incongruence 
of CMB and ICH requires careful interpretation. However, the 
majority of the patients with CMB (47/62, 76%) had no ICH. The 
explanation for this mismatch is unclear. We recently proposed a 
“two site” model of CMB and ICH, in which the specific vascular 
sites for development of CMB and ICH are different (5). In both 
CADASIL and hypertension, (arteriolar) smooth muscle cells 
and blood–brain barrier are targeted; the former has been sug-
gested as site for ICH and the latter a site for CMB (5). While 
the findings of the current study are consistent with this model, 
further mechanistic investigations are needed to confirm the 
observation.
Specific strengths of this study include the relatively large 
number of homogeneous CADASIL population (mostly R544C 
mutation), inclusion of ApoE genotype, and application of 
advanced MRI (including SWI). Our study has several limita-
tions. First, the R544C mutation was predominant; however, 
genotype–phenotype differences in CADASIL are not known 
(28). Second, this was a cross-sectional study, and prospective 
studies are needed to elucidate our findings. Third, we limited 
our observations to hemorrhagic features and did not investigate 
other manifestations of small vessel disease such as white matter 
hyperintensities and small deep infarctions. Fourth, we did not 
compare our findings to those of a non-CADASIL (e.g., CAA) or 
a non-Asian cohort, so we cannot address whether our findings 
are unique for our population group. Fifth, as some asymptomatic 
patients were likely not identified, selection bias remains a possi-
bility. Finally, while there was a topographical mismatch between 
CMB and ICH, presence of ICH may obscure presence of CMB.
Our results provide insights into interactions of CMB, hyper-
tension, and ICH in patients with CADASIL. These findings 
are consistent with a model of hemorrhagic complications in 
CADASIL in which hypertension predisposes to CMB, which in 
turn predisposes to ICH. However, this scenario requires con-
firmation in longitudinal clinical investigations. The topographic 
incongruence of CMB and ICH is currently unexplained, but is 
consistent with a model of differing vascular sites for CMB and 
ICH in CADASIL. Overall, these findings indicate that interac-
tions between CMB, hypertension, and ICH in CADASIL are 
complex and will benefit from intense mechanistic investigations.
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